Key result
CYCLOPES study evaluates an IVUS-based calcium modification algorithm for calcified coronary lesions in 500 patients.
Why the study?
Moderate-to-severe coronary calcification requires lesion modification to optimize stent delivery and expansion, but the effectiveness of an IVUS-based calcium modification algorithm has not been evaluated.
Does an IVUS-based calcium modification algorithm improve minimum stent area and reduce target lesion failure in patients undergoing PCI for moderate-to-severely calcified coronary lesions?
Observational (n=500)
Open-label
Yes
Does an IVUS-based calcium modification algorithm improve minimum stent area and reduce target lesion failure in patients undergoing PCI for moderate-to-severely calcified coronary lesions?
The CYCLOPES study is designed to evaluate the procedural and clinical efficacy of a standardized IVUS-guided calcium modification algorithm during PCI for moderately to severely calcified coronary lesions.
Answers are grounded in this paper and cite their sources.
Does not support routine IVUS-based modification yet; leaves open optimal calcium strategy pending prospective data.
INTRODUCTION: Moderate-to-severe calcification is present in ~20%-30% of patients undergoing coronary angiography. Coronary lesion modification is often necessary to facilitate optimal stent delivery and expansion, with several dedicated devices now approved for calcium modification before stent implantation. The CYCLOPES study aims to evaluate an intravascular ultrasound (IVUS) based calcium modification algorithm for the treatment of moderate-to-severely calcified coronary lesions. METHODS AND ANALYSIS: CYCLOPES is a prospective, international, multi-center, observational, single-arm study. 500 patients will be enrolled at 25 centers in Europe. Patients with planned percutaneous coronary intervention (PCI) to a native coronary artery lesion with moderate-to-severe calcification will be eligible. All PCI procedures will be IVUS guided, with drug-eluting stents implanted according to the study-specific algorithm. The co-primary endpoints are the minimum stent area (MSA) at the site of maximum calcification at the end of the index procedure (as determined by core lab analysis), and target lesion failure (TLF) at 1-year post-procedure. Prespecified secondary endpoints include: the individual components of TLF at 1 month and 1 year; the MSA measured at the end of the index procedure; strategy success (defined as successful stent delivery with ≥ 80% stent expansion and complete stent apposition with no significant edge dissection and full lesion coverage with < 50% plaque burden at proximal and distal references with TIMI 3 flow); as well as target vessel revascularization; target lesion revascularization; stent thrombosis; cardiovascular death; and acute kidney injury at 1 year. Coronary angiograms and IVUS images will be analyzed by an independent core Lab. Clinical follow-up will be performed at discharge, 30-days, and 1 year post PCI. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06678594.
No takes yet. Share an insight, caveat, or question.
O’Callaghan et al. (2025) conducted an observational in Moderate-to-severely calcified coronary lesions (n=500). IVUS-based calcium modification algorithm was evaluated on Minimum stent area (MSA) at the site of maximum calcification at the end of the index procedure, and target lesion failure (TLF) at 1-year post-procedure. The CYCLOPES study is designed to evaluate an IVUS-based calcium modification algorithm for treating moderate-to-severely calcified coronary lesions in 500 patients.
Synapse has enriched 10 related papers. Consider them for comparative context: